Emovat (Clobetasone Butyrate)

What Is Emovat and What Is It Used For?

Quick Answer: Emovat is a moderately potent topical corticosteroid (Group II) containing clobetasone butyrate. It reduces inflammation and relieves itching, and is prescribed for the treatment of acute and chronic eczema of various types.

Emovat belongs to a class of medications known as topical corticosteroids, which are widely used in dermatology for managing inflammatory skin conditions. The active ingredient, clobetasone butyrate, is classified as a moderately potent corticosteroid (Group II on the European potency scale), placing it between mild preparations such as hydrocortisone and more potent agents like betamethasone valerate. This moderate potency makes Emovat particularly well-suited for treating eczema in sensitive skin areas where stronger steroids might cause adverse effects.

The anti-inflammatory action of clobetasone butyrate works by inhibiting the release of pro-inflammatory mediators, including prostaglandins and leukotrienes, at the cellular level. When applied to eczematous skin, it reduces the characteristic redness, swelling, and itching that accompany inflammatory dermatoses. The drug also exhibits vasoconstrictive properties, which contribute to its ability to reduce erythema and oedema in the affected areas.

Emovat cream is specifically formulated for the treatment of acute and weeping eczema. The cream base contains water-miscible ingredients that allow it to spread easily on moist, inflamed skin and provide a cooling effect upon application. This makes the cream formulation ideal for eczematous conditions where there is exudate or vesicle formation, as opposed to dry, scaly dermatoses where an ointment formulation would typically be preferred.

Clinical indications for Emovat include atopic eczema (atopic dermatitis), contact dermatitis (both allergic and irritant), seborrhoeic eczema, discoid eczema, and other forms of dermatitis. The British National Formulary (BNF) classifies clobetasone butyrate as a moderately potent topical corticosteroid appropriate for use on the face and flexures for short periods, areas where more potent corticosteroids carry a higher risk of local adverse effects such as skin atrophy.

It is important to understand that Emovat treats the symptoms of eczema—inflammation and itching—rather than addressing the underlying cause of the condition. Effective eczema management typically involves identifying and avoiding triggers, maintaining skin hydration with emollients, and using topical corticosteroids like Emovat for flare-ups. Your healthcare provider can help develop a comprehensive treatment plan tailored to your specific needs.

What Should You Know Before Using Emovat?

Quick Answer: Do not use Emovat if you are allergic to clobetasone butyrate or any of its excipients, on infected skin (unless the infection is being treated), for rosacea, acne, perioral dermatitis, non-inflamed itchy skin, or skin atrophy. Use with caution near the eyes and on the face.

Contraindications

Emovat must not be used in certain situations where the risks outweigh the potential benefits. Understanding these contraindications is essential for safe use of this medication. Do not use Emovat in the following circumstances:

• Hypersensitivity: If you are allergic to clobetasone butyrate or to any of the other ingredients in Emovat (see the ingredients section below).
• Infected skin: Unless the infection is being treated concurrently with appropriate antimicrobial therapy. Topical corticosteroids can mask the signs of infection and may worsen untreated bacterial, viral, or fungal skin infections.
• Rosacea: A chronic skin condition characterised by facial redness, visible blood vessels, and sometimes pustules. Topical corticosteroids can aggravate rosacea significantly.
• Acne vulgaris: Corticosteroids can worsen acne and cause steroid-induced acne (acne steroidica) with prolonged use.
• Non-inflamed pruritus: Itchy skin that does not have an inflammatory component will not benefit from corticosteroid treatment.
• Skin atrophy: Pre-existing skin thinning or fragility is a contraindication, as corticosteroids can further compromise skin integrity.
• Perioral dermatitis: A rash around the mouth that can be caused or worsened by topical corticosteroids.
• Post-vaccination reactions: Topical corticosteroids should not be applied to vaccination sites, as they may interfere with the local immune response needed for effective vaccination.

Warnings and Precautions

Several important precautions should be observed during treatment with Emovat to minimise the risk of adverse effects and ensure optimal therapeutic outcomes:

Facial application: Exercise caution when applying Emovat to the eyelids and avoid getting the cream in the eyes. Prolonged use on the face can lead to skin thinning (dermal atrophy), telangiectasia (visible small blood vessels), and perioral dermatitis. If you experience blurred vision or other visual disturbances during treatment, contact your doctor promptly, as these may indicate ocular complications such as elevated intraocular pressure or cataract formation.

Venous leg ulcers: If you have eczema surrounding a venous leg ulcer, using a topical corticosteroid can increase the risk of allergic contact sensitisation and secondary infection around the ulcer site. Close monitoring by your healthcare provider is recommended in this scenario.

Occlusive dressings: Only use airtight or occlusive dressings over Emovat if specifically directed by your doctor. Occlusive dressings significantly enhance percutaneous absorption of topical corticosteroids, increasing the risk of both local and systemic side effects. In infants and young children, nappies (diapers) can act as occlusive dressings. If Emovat is applied under a dressing, ensure the skin is thoroughly cleaned before applying a fresh dressing to reduce the risk of infection.

Systemic absorption risk: When Emovat is used on large body surface areas, for prolonged periods, under occlusive dressings, or on damaged skin, there is an increased risk of systemic corticosteroid effects. These may include Cushing's syndrome (characterised by weight gain with altered fat distribution in the abdomen, neck, and face), thin and fragile skin, increased body hair, decreased bone density, and elevated blood pressure. In children and adolescents, growth retardation may occur. If any of these effects are observed, contact your prescribing physician to plan a gradual withdrawal—abruptly stopping treatment may result in glucocorticoid insufficiency.

Children under 12 years: Use with caution in children under 12 years of age. Children should be treated with the smallest effective amount for the shortest possible duration. Treatment should normally not exceed 7 days. If symptoms do not improve within this timeframe, consult the prescribing physician for reassessment.

Infection risk: If a skin infection develops during treatment, contact your doctor. Topical corticosteroids can suppress local immune responses, potentially allowing infections to develop or worsen.

Gradual withdrawal: Do not stop using Emovat abruptly after regular use, as the skin condition may rebound. Your doctor may recommend gradually reducing the frequency of application or switching to a less potent corticosteroid before discontinuing treatment entirely.

Pregnancy and Breastfeeding

If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Emovat. The safety of topical corticosteroids during pregnancy has not been fully established. While systemic absorption from topical application is generally minimal, healthcare providers typically weigh the benefits against the potential risks before prescribing any corticosteroid during pregnancy.

If you are breastfeeding, speak with your doctor before using Emovat. If your doctor approves its use during breastfeeding, do not apply Emovat to the breasts to ensure that the infant does not accidentally ingest the cream during feeding. Apply the cream to other body areas as directed and wash your hands thoroughly after each application.

How Does Emovat Interact with Other Drugs?

Quick Answer: Emovat can interact with CYP3A4 inhibitors such as ritonavir and itraconazole, which may increase systemic exposure to clobetasone butyrate and raise the risk of corticosteroid side effects. Always inform your healthcare provider about all medications you are taking.

Although topical corticosteroids like Emovat are applied to the skin and have relatively low systemic absorption under normal use conditions, certain drug interactions are clinically relevant. These interactions primarily occur through inhibition of the cytochrome P450 3A4 (CYP3A4) enzyme system, which is involved in the metabolism of corticosteroids that are absorbed systemically.

The concurrent use of potent CYP3A4 inhibitors can reduce the metabolic clearance of clobetasone butyrate that has been absorbed through the skin, leading to higher systemic levels and an increased risk of systemic corticosteroid effects. This interaction becomes more significant when Emovat is applied to large surface areas, used under occlusive dressings, applied to damaged skin, or used for extended periods.

If you are taking any of the medications listed above, or other CYP3A4 inhibitors, inform your doctor or pharmacist before using Emovat. Your healthcare provider may need to adjust the treatment area, duration, or frequency of Emovat application, or consider an alternative topical treatment. Always tell your healthcare provider about all medicines you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements.

It is generally advisable to avoid applying other topical medications to the same skin area at the same time as Emovat. If you also use an emollient (moisturiser), wait several minutes after applying Emovat to allow it to be absorbed before applying the emollient. This ensures that the corticosteroid can penetrate the skin effectively and is not diluted or removed by the emollient.

What Is the Correct Dosage of Emovat?

Quick Answer: Apply a thin layer of Emovat cream to the affected area and gently massage in, typically once or twice daily as directed by your doctor. Do not use continuously for more than 4 weeks. Children should use the minimum effective amount for no longer than 7 days.

Always use Emovat exactly as your doctor has instructed. If you are unsure about any aspect of your treatment, consult your doctor or pharmacist for clarification. The correct dosage depends on the severity and extent of the skin condition, the area being treated, and the patient's age.

Adults

Children

Elderly and Patients with Hepatic or Renal Impairment

Missed Dose

If you forget to apply Emovat, use it as soon as you remember and then continue with your regular application schedule. Do not apply extra cream to compensate for a missed dose. Simply resume your normal routine.

Overdose

Acute overdose with topical corticosteroids is unlikely. However, chronic overuse or misuse of Emovat can lead to systemic corticosteroid effects, including adrenal suppression, Cushing's syndrome, and other metabolic disturbances. If you suspect that you have used too much Emovat over an extended period, contact your doctor, hospital, or poison control centre for a risk assessment and appropriate guidance.

What Are the Side Effects of Emovat?

Quick Answer: Uncommon side effects include skin thinning and stretch marks. Very rare side effects include adrenal suppression, Cushing's syndrome, cataracts, glaucoma, and growth retardation in children. Local reactions such as burning, itching, and redness may also occur. The risk increases with prolonged use, large treatment areas, and occlusive dressings.

Like all medicines, Emovat can cause side effects, although not everybody gets them. The risk of side effects is generally low when Emovat is used as directed for short-term treatment of localised eczema. However, the risk increases significantly when the medication is applied to large body surface areas, used for extended periods, used under occlusive dressings, or applied to damaged or thin skin. In infants and young children, the nappy area can act as an occlusive environment, increasing percutaneous absorption.

Most local side effects of topical corticosteroids are reversible upon discontinuation of the medication, although skin thinning may take considerable time to resolve. The risk of systemic side effects is generally very low with a moderately potent corticosteroid like clobetasone butyrate when used appropriately. If you experience any side effects, particularly those affecting your vision or general wellbeing, report them to your healthcare provider promptly.

If you notice signs of skin infection (increased redness, warmth, pain, pus, or spreading of the affected area), contact your doctor, as corticosteroid therapy may need to be paused while the infection is treated. In some cases, your doctor may prescribe a combination treatment with an antimicrobial agent.

How Should You Store Emovat?

Quick Answer: Store Emovat at or below 25°C (77°F). Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging. Do not dispose of in wastewater or household waste.

Proper storage of Emovat is essential to maintain its efficacy and safety throughout its shelf life. Store the cream at a temperature not exceeding 25°C (77°F). Do not freeze the cream, and keep the tube tightly closed when not in use to prevent contamination and drying out of the product.

Keep Emovat out of the sight and reach of children at all times. Store it in a secure location where children cannot access it. Do not use Emovat after the expiry date (marked as "EXP" or equivalent on the packaging). The expiry date refers to the last day of the stated month.

When you have finished your treatment or the medication has expired, do not dispose of Emovat in wastewater (down the drain) or in household waste (rubbish bin). Ask your pharmacist how to properly dispose of medicines that are no longer needed. Proper disposal helps protect the environment and prevents accidental exposure.

What Does Emovat Contain?

Quick Answer: Each gram of Emovat cream contains 0.5 mg of clobetasone (as clobetasone butyrate) as the active ingredient, along with excipients including glycerol monostearate, cetostearyl alcohol, chlorocresol (preservative), and purified water.

Active Ingredient

Each gram of Emovat cream contains 0.5 mg of clobetasone (as clobetasone butyrate), corresponding to a concentration of 0.05%. Clobetasone butyrate is a synthetic glucocorticoid with potent local anti-inflammatory activity and relatively low systemic absorption, making it suitable for topical dermatological use.

Excipients (Inactive Ingredients) – Cream

The cream formulation contains the following excipients: glycerol monostearate, cetostearyl alcohol, stearoyl macrogol glycerides, synthetic beeswax (containing paraffin and carnauba wax), sodium citrate, citric acid monohydrate, dimethicone (silicone oil), glycerol, purified water, and chlorocresol (preservative).

Packaging

Emovat cream is a white cream supplied in aluminium tubes containing 25 g, 30 g, or 100 g. Not all pack sizes may be marketed in your country. The marketing authorisation holder is GlaxoSmithKline, and the product is manufactured by Delpharm Poznań S.A. in Poland and GlaxoSmithKline Trading Services Limited in Ireland.

Does Emovat Affect Your Ability to Drive?

Quick Answer: No. Emovat has no known effect on the ability to drive vehicles or operate machinery.

Emovat cream is applied topically and has no known effects on the central nervous system. There is no evidence that clobetasone butyrate impairs the ability to drive or use machines. You can continue your normal daily activities, including driving and operating machinery, while using Emovat. However, if you experience blurred vision (a very rare side effect), you should avoid driving until your vision returns to normal and consult your doctor.

Editorial Team

This article has been developed and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in dermatology and clinical pharmacology with extensive experience in evidence-based medicine.